50d87a6b-8e96-4964-9f23-53cc48c7d9ff
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 57.8097193702943
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.180
- E2F_TARGETS+0.140
- MYC_TARGETS_V2+0.080
- MITOTIC_SPINDLE+0.040
- MYC_TARGETS_V1+0.040
- WNT_BETA_CATENIN_SIGNALING+0.030
- PROTEIN_SECRETION+0.020
- UV_RESPONSE_DN-0.020
- DNA_REPAIR-0.030
- ESTROGEN_RESPONSE_EARLY-0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- IL6_JAK_STAT3_SIGNALING-0.440
- INFLAMMATORY_RESPONSE-0.440
- COMPLEMENT-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- ALLOGRAFT_REJECTION-0.370
- CHOLESTEROL_HOMEOSTASIS-0.360
- COAGULATION-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b68594bb-fca3-4f05-a9fa-1e6e88eb4fc5 | — | — | 0.918 |
| 2 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.900 |
| 3 | s_150324_3b | EPN | Posterior Fossa EPN | 0.897 |
| 4 | SRR650167 | — | — | 0.897 |
| 5 | MBCProject_0381_T1_RNA | — | B | 0.896 |
| 6 | SJEPD031175_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.895 |
| 7 | 88306 | EPN | Supratentorial EPN | 0.890 |
| 8 | BS_VAAHBH60 | EPN | Supratentorial EPN | 0.882 |
| 9 | BS_QRDT19KS | medulloblastoma | — | 0.877 |
| 10 | SRR17866817 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |